Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 2 54-2, 2003, Pages

  Yuan, Zuyi ^a   Kishimoto, Chiharu ^a   Sano, Hideto ^a   Shioji, Keisuke ^a   Xu, Yang ^a   Yokode, Masayuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Fc receptor; Knockout mice

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; LIPID; SERUM ALBUMIN; VENOGLOBULIN IH;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOTOXICITY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOTHERAPY; LIPID BLOOD LEVEL; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0038299304     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00926.2002     Document Type: Article

References (34)

1. Bendtzen K, Hansen MB, Ross C, and Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 19: 209-211, 1998.
2. Blasczyk R, Westhoff U, and Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341: 789-790, 1993.
3. Dansky HM, Charlton SA, Harper MM, and Smith JD. T and B lymphocytes play a minor role in atherosclerosis plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 94: 4642-4646, 1997.
4. Deo YM, Graziano RF, Repp R, and van de Winkel JG. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies. Immunol Today 18: 127-135, 1997.
5. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, and Meyer J. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 105: 15-21, 2002.
6. Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, Cheze S, Legouffe E, Hulin C, Grange MJ, Fain O, and Bierling P. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet 359: 23-29, 2002.
7. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, and Schindler C. IFN-γ potentiates atherosclerosis in Apo E knock-out mice. J Clin Invest 99: 2752-2761, 1997.
8. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1876-1890, 2001.
9. Huang Y, Jaffa A, Koskinen S, Takei A, and Lopes-Virella MF. Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 19: 1600-1607, 1999.
10. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, and Kazatchkine MD. Anti-CD 4 activity of normal human immunoglobulin G for therapeutic use? Ther Immunol 1: 269-277, 1994.
11. Jonasson L, Holm J, Skalli O, Bondjers G, and Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Atherosclerosis 6: 131-138, 1986.
12. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, and Kazatchkine MD. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97: 865-869, 1996.
13. Kazatchkine MD and Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755, 2001.
14. Kishimoto C and Abelmann WH. In vivo significance of T cell in the development of coxsackievirus B3 myocarditis in mice: antigen-specific T cells aggravate cardiac injury. Circ Res 67: 589-598, 1990.
15. Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, and Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol 36: 1979-1984, 2000.
16. Konishi H, Katoh Y, Takaya N, Kashiwakura Y, Itoh S, Ra C, and Daida H. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation 105: 912-916, 2002.
17. Lam L, Whitsett CF, McNicholl JM, Hodge TW, and Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 346: 678, 1993.
18. Libby P and Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 64: 5-15, 1991.
19. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M, and Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis 135: 161-170, 1997.
20. Mayr M, Kiechl S, Willeit J, Wick G, and Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 102: 833-839, 2000.
21. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, Feingold KR, and Grunfeld C. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol 20: 1536-1542, 2000.
22. Murayama T, Yokode M, Kataoka H, Imabayashi T, Yoshida H, Sano H, Nishikawa S, Nishikawa S, and Kita T. Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice. Circulation 99: 1740-1746, 1999.
23. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, and Hansson GK. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 102: 910-918, 1998.
24. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999.
25. Samuelsson A, Towers TL, and Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486, 2001.
26. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, and Kita T. Functional blockade of platelet-derived growth factor receptor-β but not of receptor-α prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103: 2955-2960, 2001.
27. Shioji K, Kishimoto C, and Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res 89: 540-546, 2001.
28. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, and Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 92: 8264-8268, 1995.
29. Song L, Leung C, and Schindler C. Lymphocytes are important in early atherosclerosis. J Clin Invest 108: 251-259, 2001.
30. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, and Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92: 3893-3897, 1995.
31. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, and Bendtzen K. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91: 2054-2061, 1998.
32. Takada H, Kishimoto C, and Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: antiviral and anti-inflammatory effects. Circulation 92: 1604-1611, 1995.
33. Watson SP and Gibbins J. Collagen receptor signaling in platelets: extending the role of the ITAM. Immunol Today 19: 260-264, 1998.
34. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102: 2919-2922, 2000.